The current and future burden of heart failure in Portugal.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 18 07 2018
accepted: 21 11 2018
pubmed: 9 1 2019
medline: 17 5 2019
entrez: 9 1 2019
Statut: ppublish

Résumé

Heart failure (HF) is a clinical syndrome with significant social and economic burden. We aimed to estimate the burden of HF in mainland Portugal over a 22-year time horizon, between 2014 and 2036. Heart failure burden was measured in disability-adjusted life years (DALYs), resulting from the sum of years of life lost (YLL) due to premature death and years lost due to disability (YLD). YLL were estimated based on the Portuguese mortality rates reported by the European Detailed Mortality Database. For YLD, disease duration and the overall incidence were estimated using an epidemiological model developed by the World Health Organization (DISMOD II). Disability weights were retrieved from published literature. The impact of ageing was estimated with a shift-share analysis using official demographic projections. In 2014, 4688 deaths were attributed to HF, corresponding to 4.7% of the total deaths in mainland Portugal. DALYs totalled 21 162, 53.9% due to premature death (YLL: 11 398) and 46.1% due to disability (YLD: 9765). Considering only population ageing over a 22-year horizon, the deaths and burden of HF are expected to increase by 73.0% and 27.9%, respectively, reaching 8112 deaths and 27 059 DALYs lost due to HF in 2036. DALY's growth is mainly driven by the increase of YLL, whose contribution to overall burden will increase to 62.0%. Heart failure is an emerging and growing health problem where significant health gains may be obtained. The projected significant increase of HF burden highlights the need to set HF as a priority for healthcare system.

Identifiants

pubmed: 30620150
doi: 10.1002/ehf2.12399
pmc: PMC6437427
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

254-261

Informations de copyright

© 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Références

Rev Port Cardiol. 2018 Feb;37(2):97-104
pubmed: 29325804
J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133
pubmed: 24491689
JACC Heart Fail. 2013 Feb;1(1):1-20
pubmed: 24621794
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur Heart J. 2002 Dec;23(23):1861-6
pubmed: 12445535
Bull World Health Organ. 1994;72(3):429-45
pubmed: 8062401
Rev Port Cardiol. 2017 Jan;36(1):1-8
pubmed: 27988232
Eur J Heart Fail. 2002 Aug;4(4):531-9
pubmed: 12167394
Popul Health Metr. 2003 Apr 14;1(1):4
pubmed: 12773212
Rev Port Cardiol. 2015 Jan;34(1):1-11
pubmed: 25534665
Value Health. 2014 Nov;17(7):A626
pubmed: 27202212
Value Health. 2014 Nov;17(7):A339
pubmed: 27200619
Lancet. 2018 Feb 10;391(10120):572-580
pubmed: 29174292
Hellenic J Cardiol. 2019 May - Jun;60(3):185-188
pubmed: 29601956
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
Alcohol Clin Exp Res. 2010 Aug;34(8):1442-9
pubmed: 20528821
ESC Heart Fail. 2019 Apr;6(2):254-261
pubmed: 30620150
ESC Heart Fail. 2014 Sep;1(1):4-25
pubmed: 28834669
Hellenic J Cardiol. 2017 Jan - Feb;58(1):1-3
pubmed: 28396053

Auteurs

Miguel Gouveia (M)

Católica Lisbon School of Business and Economics, Universidade Católica Portuguesa, Lisbon, Portugal.

Raquel Ascenção (R)

Centro de Estudos de Medicina Baseada na Evidência (CEMBE), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Francesca Fiorentino (F)

Centro de Estudos de Medicina Baseada na Evidência (CEMBE), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

João Costa (J)

Centro de Estudos de Medicina Baseada na Evidência (CEMBE), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Lisbon, Portugal.
Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal.

Daniel Caldeira (D)

Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Lisbon, Portugal.

Paula Broeiro-Gonçalves (P)

Agrupamento de Centros de Saúde Lisboa Central, Unidade de Cuidados de Saúde Personalizados dos Olivais, Lisbon, Portugal.
Institituto de Medicina Preventiva e Saúde Pública (IMPSP), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Candida Fonseca (C)

Centro Hospitalar de Lisboa Ocidental, Heart Failure Unit, Department of Internal Medicine and Day Hospital, Hospital São Francisco Xavier, Lisbon, Portugal.

Margarida Borges (M)

Centro de Estudos de Medicina Baseada na Evidência (CEMBE), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Lisbon, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH